Enlicitide Decanoate Reduces Cholesterol

This is a news story, published by Yahoo Finance, that relates primarily to Merck & Co. news.

drug discoveries news

For more drug discoveries news, you can click here:

more drug discoveries news

Yahoo Finance news

For more news from Yahoo Finance, you can click here:

more news from Yahoo Finance

About the Otherweb

Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about

cholesterol

. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest pharmaceuticals news, innovative health solutions news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!

Merck

Insider Trading & Hedge Fund Data, and Investment Newsletter From Insider Monkey

•

Health

Merck’s Cholesterol Medication Achieves Primary Endpoint in Two Trials

Summary

Nutrition label

75% Informative

Merck & Co. , Inc. announced its drug, enlicitide decanoate, achieved its primary goal of lowering a specific type of cholesterol in two late-stage clinical trials.

The medication is being studied as a potential treatment for hyperlipidemia, a condition marked by high levels of fat in the bloodstream.

VR Score

Informative language

Neutral language

Article tone

informal

Language

English

Language complexity

Offensive language

not offensive

Hate speech